In particular, wepresent compound 40 (ARN24092) as a backup/follow-uplead with in vivo efficacy in a mouse model of DS.These results further strengthen the potential of this new class ofcompounds for the treatment of core symptoms of brain disorders characterizedby the defective NKCC1/KCC2 expression ratio. Here, SLC12A2 is linked to brain disorder.